Free Trial

Eupraxia Pharmaceuticals (EPRX) SEC Filings & 10K Form

Eupraxia Pharmaceuticals logo
$5.59 -0.07 (-1.24%)
Closing price 09/24/2025 04:00 PM Eastern
Extended Trading
$5.50 -0.09 (-1.52%)
As of 08:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Eupraxia Pharmaceuticals SEC Filings

DateFilerForm TypeView
09/23/2025
2:51 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2025
2:54 PM
Eupraxia Pharmaceuticals (Filer)
Form SUPPL
09/23/2025
10:07 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/22/2025
3:57 PM
Eupraxia Pharmaceuticals (Filer)
Form SUPPL
09/22/2025
3:43 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/19/2025
2:53 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/02/2025
7:15 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/22/2025
4:23 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/08/2025
6:00 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2025
1:15 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/05/2025
6:15 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2025
4:10 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2025
6:48 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2025
6:02 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2024
7:57 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/13/2024
4:01 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/08/2024
10:49 AM
Eupraxia Pharmaceuticals (Filer)
Form D
Notice of Exempt Offering of Securities 
11/07/2024
4:17 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/31/2024
6:39 PM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/28/2024
6:02 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2024
7:06 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/10/2024
6:01 AM
Eupraxia Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:EPRX) was last updated on 9/25/2025 by MarketBeat.com Staff
From Our Partners